CD8A and neoplasm: Therefore, up-regulated SLC27A2, KLRB1, IGKV1OR2-108 and IGHV1-12 in the low-risk score group synergistically inhibit tumor progression and activating immune response by regulating CD8+ T cells, NK cells and immunoglobulin.